[1] |
NING Xiao, GAO Guanghui, JIN Shaoming, LIU Tongtong, PEI Yusheng, CAO Jin.
Determination of erythromycin ointment content based on on-line column switching and liquid chromatography
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 152-155.
|
[2] |
CONG Duanduan, XUE Wei, LIU Yue, QI Wenyuan, LIU Xiaohui, WANG Juan, LI Kexin, HU Xin.
Management of Safety Information in Prescription Drug Labeling in China, Japan and the United States
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(3): 245-249.
|
[3] |
WANG Yanchun, WANG Jianqiang.
Research Progress in Clinical Application of Shuganning Injection
[J]. Chinese Journal of Pharmacovigilance, 2020, 17(8): 543-547.
|
[4] |
LI Sizheng, HU Guang, HE Jingcheng, HU Yuchi, LI Zhiyong, JIN Hongtao.
The Role of Renin-angiotensin System in COVID-19 and Drug Intervention
[J]. Chinese Journal of Pharmacovigilance, 2020, 17(5): 267-271.
|
[5] |
TIAN Chunhua, XIA Dongsheng.
"Double Classification" Management of Prescription Drugs and Non-prescription Drugs in China based on British System
[J]. Chinese Journal of Pharmacovigilance, 2020, 17(12): 883-884.
|
[6] |
ZHU Lan, Shao Bo, XIA Dongsheng.
Selection and Switch-to-OTC of Chinese Patent Medicines in China
[J]. Chinese Journal of Pharmacovigilance, 2020, 17(11): 785-789.
|
[7] |
QIU Caixia, YANG Cuiping, JIN Hongtao.
Research Progress in Mechanisms of Drug-induced Kidney Injury
[J]. Chinese Journal of Pharmacovigilance, 2019, 16(11): 688-694.
|
[8] |
LI En-can, HE Jiu-ming, JIN Hong-tao, LIN Ni.
Research Progress of Pharmacological Activity and Toxicity of 5-Hydroxymethylfurfural
[J]. Chinese Journal of Pharmacovigilance, 2018, 15(4): 210-215.
|
[9] |
WANG Shuo, CHEN Naihong, YUAN Yuhe.
Advances in Research on Targeted Treatment of Alzheimer's Disease
[J]. Chinese Journal of Pharmacovigilance, 2018, 15(12): 755-760.
|
[10] |
FENG Hong-yun, FAN Yan, WU Gui-zhi, DONG Duo.
Analysis of the Perception of Risk on Drug-induced Progressive Multifocal Leukoencephalopathy
[J]. Chinese Journal of Pharmacovigilance, 2016, 13(9): 557-562.
|
[11] |
FENG Hong-yun, FAN Yan, WU Gui-zhi, DONG Duo.
Research of the Risk Factors and Practice of Drug Risk Management on Drug-induced Progressive Multifocal Leukoencephalopathy
[J]. Chinese Journal of Pharmacovigilance, 2016, 13(8): 472-475.
|
[12] |
SHI Liang,SUN Rong.
Advances in Establishment of Animal Models with Hepatic Cirrhosis and Thinking about Efficacy Evaluation of Traditional Chinese Medicine
[J]. Chinese Journal of Pharmacovigilance, 2016, 13(1): 32-35.
|
[13] |
TIAN Yi, YANG Yue, TIAN Li-juan.
Progress and Implication of FDA Risk Communication in the United States
[J]. Chinese Journal of Pharmacovigilance, 2016, 13(1): 24-27.
|
[14] |
QIAN Zhen,JIANG Guo-rong*.
Research Progress in Anti-tumor Effect of Polysaccharides
[J]. Chinese Journal of Pharmacovigilance, 2015, 12(2): 96-98.
|
[15] |
WANG Pei-jie, WANG Jia-lun, YI Zhi-wei, Dong Yan-fei, WANG Pu.
Literature Analysis of 40 Cases of Adverse Drug Reactions of Nonprescription Chinese Patent Medicines for Diseases of Throat Department
[J]. Chinese Journal of Pharmacovigilance, 2015, 12(11): 690-692.
|